Stemline Therapeutics (STML)

[biotech_researcher]

Approved by FDA for BPDCN, rare blood cancer (500-1000 pts annually) with CD113 mutation. No other treatment available. STML has a Very robust pipeline.

$STML Upcoming Tagraxofusp in BPDCN pivotal clinical trial publication in NEJM April 25 edition. No real surprises. Of 29 patients not previously treated, 90% ORR, 13 bridged to transplant, and 52% alive at 2 years. In 13 prev tx'd, ORR=67%, and median OS = 8.5 mos. CLS in 1/44